Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors
Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.
1. A pharmaceutical composition comprising a synergistic combination of two or more human immunodeficiency virus (HIV) fusion/entry inhibitors in amounts effective for treatment of HIV, wherein the HIV fusion/entry inhibitors are selected from the group consisting of T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide.
2. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20 and T-1249.
3. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20 and T-1144.
4. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-1249 and T-1144.
5. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20 and C34.
6. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-1249 and C34.
7. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-1144 and C34.
8. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20, T-1249, and T-1144.
9. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20, T-1249, and C34.
10. The pharmaceutical composition of claim 1 , wherein the HIV fusion/entry inhibitors comprise T-20 and sifuvirtide.